Merck KGaA
General ticker "MKGAF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $59.3B (TTM average)
Merck KGaA follows the US Stock Market performance with the rate: 39.2%.
Estimated limits based on current volatility of 3.4%: low 150.04$, high 160.70$
Factors to consider:
- Company pays dividends (annually): last record date 2026-04-28, amount 2.58$ (Y1.68%)
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [114.77$, 170.62$]
- 2026-12-31 to 2027-12-31 estimated range: [116.89$, 173.79$]
Financial Metrics affecting the MKGAF estimates:
- Negative: with PPE of 17.4 at the end of fiscal year the price was high
- Positive: 6.59 < Operating cash flow per share per price, % of 7.42
- Positive: Operating profit margin, % of 19.26 > 18.39
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 4.78
- Positive: Inventory ratio change, % of -0.41 <= 0
- Positive: 42.59 < Shareholder equity ratio, % of 54.88 <= 64.29
- Positive: Interest expense per share per price, % of 0.49 <= 0.73
Short-term MKGAF quotes
Long-term MKGAF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €20,993.00MM | €21,156.00MM | €21,094.10MM |
| Operating Expenses | €17,384.00MM | €17,511.00MM | €17,030.62MM |
| Operating Income | €3,609.00MM | €3,645.00MM | €4,063.48MM |
| Non-Operating Income | €-125.00MM | €-109.00MM | €-756.72MM |
| Interest Expense | €272.00MM | €292.00MM | €261.90MM |
| R&D Expense | €2,445.00MM | €2,279.00MM | €2,381.11MM |
| Income(Loss) | €3,484.00MM | €3,536.00MM | €3,306.76MM |
| Taxes | €650.00MM | €751.00MM | €692.74MM |
| Net Income(Loss)* | €2,824.00MM | €2,777.00MM | €2,607.02MM |
| Stockholders Equity | €26,680.00MM | €29,912.00MM | €28,581.29MM |
| Inventory | €4,637.00MM | €4,484.00MM | €4,560.29MM |
| Assets | €48,495.00MM | €51,567.00MM | €52,080.49MM |
| Operating Cash Flow | €3,784.00MM | €4,586.00MM | €3,930.53MM |
| Capital expenditure | €2,023.00MM | €2,184.00MM | €1,583.41MM |
| Investing Cash Flow | €-1,892.00MM | €-3,050.00MM | €-4,259.40MM |
| Financing Cash Flow | €-1,732.00MM | €-985.00MM | €627.76MM |
| Earnings Per Share** | €6.49 | €6.39 | €6.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.